This study evaluates the efficacy and safety of two weeks treatment of DNK333 in patients with COPD and cough.

Inclusion Criteria:

• Mild to moderate COPD
• Forced expiratory volume in 1 second (FEV1) ≥30% predicted
• FEV1/FVC (forced vital capacity) <70%
• Significant amount of cough and minimal amount of sputum production, both as judged by self reporting

Exclusion criteria:

• Upper or lower airway infection within 4 weeks prior to screening
• COPD exacerbation within 4 weeks prior to screening
• Past history or current diagnosis of congestive heart failure, cirrhosis or hepatic failure
• History of lung cancer or pulmonary resection/thoracic radiotherapy

Other protocol-defined inclusion/exclusion criteria may apply